John Allan, MD

Articles

Unmet Needs and Future Directions in Care in CLL

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan M. O'Brien MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

March 8th 2023

Closing out their discussion on novel treatment strategies in CLL, expert hematologist-oncologists address unmet needs and future directions in care.

Chronic Lymphocytic Leukemia: Emerging Therapeutic Targets

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan M. O'Brien MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

March 8th 2023

An in-depth review of novel therapeutic targets making their way into clinical trials for patients with chronic lymphocytic leukemia.

Optimal Sequencing of Therapy in Chronic Lymphocytic Leukemia

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan M. O'Brien MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

March 1st 2023

Following their discussion on novel therapeutic agents in chronic lymphocytic leukemia, panelists consider how these agents might be sequenced for optimal efficacy.

Evolving Role of Anti-CD20 Therapy in Chronic Lymphocytic Leukemia

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan M. O'Brien MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

March 1st 2023

Expert perspectives on the novel use of ant-CD20 therapy as first-line or combination treatment in chronic lymphocytic leukemia.

Novel Strategies in Managing Patients With High-Risk Chronic Lymphocytic Leukemia

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan O’Brien, MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

February 22nd 2023

Key opinion leaders provide their perspective on the optimal management of high-risk chronic lymphocytic leukemia with novel therapeutic agents.

Venetoclax + Second Generation BTKi Combination Therapy in R/R CLL

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan M. O'Brien MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

February 22nd 2023

Clinical trial updates evaluating the combination of venetoclax with second-generation BTK inhibitors acalabrutinib and zanabrutinib, respectively.

Clinical Trials in R/R CLL: Venetoclax + Ibrutinib Combination Therapy

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan M. O'Brien MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

February 15th 2023

Key updates from clinical trials evaluating the combination of venetoclax and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Fixed Duration Venetoclax Therapy in Relapsed/Refractory CLL

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan M. O'Brien MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

February 15th 2023

Centering focus on the relapsed/refractory setting of CLL, panelists consider the use of fixed-duration venetoclax following updated clinical trial data in this setting.

Non-Covalent BTK Inhibitors in CLL: Updates from Clinical Trials With Pirtobrutinib

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan M. O'Brien MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

February 8th 2023

Expert perspectives on the role of non-covalent BTK inhibitors in managing patients diagnosed with chronic lymphocytic leukemia.

Chronic Lymphocytic Leukemia: Real World and QoL Evidence With BTKi

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan M. O'Brien MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

February 8th 2023

A panel of key opinion leaders elucidates real-world data with BTK inhibitors in CLL and considers the importance of patient-reported outcomes on quality of life.

Selecting the Appropriate BTKi in Chronic Lymphocytic Leukemia

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan M. O'Brien MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

February 1st 2023

Comprehensive perspectives on clinical factors that help to inform the selection of appropriate BTK inhibitor therapy for patients with chronic lymphocytic leukemia.

Head-to-Head Trials of BTKi in Chronic Lymphocytic Leukemia

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan M. O'Brien MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

February 1st 2023

Shared insight on and reactions to head-to-head comparison trials between novel BTK inhibitors in the setting of chronic lymphocytic leukemia.

BTK Inhibitors in Relapsed/Refractory Chronic Lymphocytic Leukemia

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan M. O'Brien MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

January 25th 2023

Switching focus to the second-line setting, expert hematologist-oncologists evaluate the continued role of BTK inhibitors in chronic lymphocytic leukemia.

Second Generation BTKi in CLL: First-Line Treatment With Acalabrutinib or Zanubrutinib

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan M. O'Brien MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

January 25th 2023

Centering discussion on second-generation BTK inhibitors, expert panelists review clinical data behind first-line acalabrutinib and zanubrutinib, respectively.

Chronic Lymphocytic Leukemia: Role of First-Generation BTK Inhibitors

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan M. O'Brien MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

January 18th 2023

A brief review of first-line BTK inhibition in chronic lymphocytic leukemia following the advent of ibrutinib, along with considerations for minimal residual disease testing in this setting.

Brief Overview of Chronic Lymphocytic Leukemia

Sonali M. Smith, MD;Nicole Lamanna, MD;Susan M. O'Brien MD;Sameer Parikh, MD;Ryan W. Jacobs, MD;John Allan, MD

January 18th 2023

Expert hematologist-oncologist Sonali Smith, MD, shares a brief overview of chronic lymphocytic leukemia (CLL), highlighting incidence, prognosis, and molecular subsets.

John N. Allan, MD, of Weill Cornell Medical College

Dr. Allan on the Safety Profile of Ibrutinib in High-Risk CLL

John Allan, MD

December 23rd 2020

John N. Allan, MD, discusses the safety profile of ibrutinib in high-risk chronic lymphocytic leukemia.

Dr. Allan on the Use of Vecabrutinib Therapy in B-Cell Malignancies

John Allan, MD

January 31st 2020

John N. Allan, MD, assistant attending physician at NewYork-Presbyterian Hospital and assistant professor of medicine, Weill Cornell Medical College, Cornell University, discusses the use of vecabrutinib (SNS-062) therapy in patients with B-cell malignancies.